Tags

Type your tag names separated by a space and hit enter

Long-term Impact of a "3 + 0" Schedule for 7- and 13-Valent Pneumococcal Conjugate Vaccines on Invasive Pneumococcal Disease in Australia, 2002-2014.
Clin Infect Dis. 2017 Jan 15; 64(2):175-183.CI

Abstract

BACKGROUND

Australia introduced universal 7-valent pneumococcal conjugate vaccine (PCV7) from 2005, replaced by 13-valent PCV (PCV13) in 2011, uniquely among high-income countries giving doses at 2, 4, and 6 months (3 + 0 schedule). Data on impact of a timely 3 + 0 PCV schedule with high coverage are sparse, with none for PCV13.

METHODS

We used national surveillance of invasive pneumococcal disease (IPD) from 2002 for baseline and appropriate later comparison periods to calculate incidence rate ratios (IRRs) by serotype and age using a Poisson model. PCV coverage was assessed from the Australian Childhood Immunisation Register.

RESULTS

After 9 years of timely 3-dose PCV coverage of >92%, all-age IPD in Australia almost halved (IRR, 0.53; 95% confidence interval [CI], .50-.57), but differed by PCV era. Reductions in IPD due to vaccine serotypes from PCV7 (IRR, 0.20; CI, .17-.22) were about 2-fold greater than for IPD due to extra serotypes in PCV13 (13v-non7v) in a similar period (IRR, 0.58; CI, .51-.66). Post-PCV13 declines in serotype 19A IPD in persons aged <2 years (IRR, 0.23; CI, .13-.35) and ≥2 years (IRR, 0.35; CI, .28-.44) differed from other 13v-non7v IPD (IRR, 0.73; CI, .35-1.48 for those aged <2 years and IRR, 0.96; CI, .81-1.15 for those ≥2 years). Meningitis due to vaccine serotypes nearly disappeared in children eligible for 3 PCV13 doses. IPD due to non-PCV13 serotypes increased by 30% compared with 76% for non-PCV7 serotypes in equivalent period of vaccine use.

CONCLUSIONS

Reductions in vaccine-type IPD post-PCV13 were inferior to Australian experience with PCV7 and reports from high-income countries giving a PCV booster dose. Applicability of findings to other settings would depend on age of IPD onset, serotype profile, and timeliness of vaccination.

Links

Publisher Full Text (DOI)

Authors+Show Affiliations

Jayasinghe S
National Centre for Immunisation Research and Surveillance for Vaccine Preventable Diseases, Westmead; sanjay.jayasinghe@health.nsw.gov.au. Discipline of Child and Adolescent Health, University of Sydney, and.
Menzies R
School of Public Health and Community Medicine, University of New South Wales, Sydney.
Chiu C
National Centre for Immunisation Research and Surveillance for Vaccine Preventable Diseases, Westmead. Discipline of Child and Adolescent Health, University of Sydney, and.
Toms C
Office of Health Protection, Australian Government Department of Health, Canberra.
Blyth CC
Department of Infectious Diseases and Microbiology, Princess Margaret Hospital, School of Paediatrics and Child Health and Telethon Kids Institute, University of Western Australia, Perth.
Krause V
Centre for Disease Control, Department of Health, Darwin, Northern Territory; and.
McIntyre P
National Centre for Immunisation Research and Surveillance for Vaccine Preventable Diseases, Westmead. Discipline of Child and Adolescent Health, University of Sydney, and. School of Public Health, University of Sydney, Sydney, Australia.

MeSH

AdolescentAdultAgedAged, 80 and overAustraliaChildChild, PreschoolFemaleHeptavalent Pneumococcal Conjugate VaccineHistory, 21st CenturyHumansImmunization ScheduleIncidenceInfantMaleMiddle AgedOutcome Assessment, Health CarePneumococcal InfectionsPneumococcal VaccinesPopulation SurveillanceSerogroupStreptococcus pneumoniaeVaccinationVaccines, ConjugateYoung Adult

Pub Type(s)

Historical Article
Journal Article

Language

eng

PubMed ID

27986682

Citation

Jayasinghe, Sanjay, et al. "Long-term Impact of a "3 + 0" Schedule for 7- and 13-Valent Pneumococcal Conjugate Vaccines On Invasive Pneumococcal Disease in Australia, 2002-2014." Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America, vol. 64, no. 2, 2017, pp. 175-183.
Jayasinghe S, Menzies R, Chiu C, et al. Long-term Impact of a "3 + 0" Schedule for 7- and 13-Valent Pneumococcal Conjugate Vaccines on Invasive Pneumococcal Disease in Australia, 2002-2014. Clin Infect Dis. 2017;64(2):175-183.
Jayasinghe, S., Menzies, R., Chiu, C., Toms, C., Blyth, C. C., Krause, V., & McIntyre, P. (2017). Long-term Impact of a "3 + 0" Schedule for 7- and 13-Valent Pneumococcal Conjugate Vaccines on Invasive Pneumococcal Disease in Australia, 2002-2014. Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America, 64(2), 175-183. https://doi.org/10.1093/cid/ciw720
Jayasinghe S, et al. Long-term Impact of a "3 + 0" Schedule for 7- and 13-Valent Pneumococcal Conjugate Vaccines On Invasive Pneumococcal Disease in Australia, 2002-2014. Clin Infect Dis. 2017 Jan 15;64(2):175-183. PubMed PMID: 27986682.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Long-term Impact of a "3 + 0" Schedule for 7- and 13-Valent Pneumococcal Conjugate Vaccines on Invasive Pneumococcal Disease in Australia, 2002-2014. AU - Jayasinghe,Sanjay, AU - Menzies,Rob, AU - Chiu,Clayton, AU - Toms,Cindy, AU - Blyth,Christopher C, AU - Krause,Vicki, AU - McIntyre,Peter, Y1 - 2016/10/21/ PY - 2016/07/25/received PY - 2016/10/18/accepted PY - 2016/12/18/pubmed PY - 2017/12/23/medline PY - 2016/12/18/entrez KW - Australia KW - PCV13 KW - PCV7 KW - invasive pneumococcal disease KW - vaccine impact. SP - 175 EP - 183 JF - Clinical infectious diseases : an official publication of the Infectious Diseases Society of America JO - Clin Infect Dis VL - 64 IS - 2 N2 - BACKGROUND: Australia introduced universal 7-valent pneumococcal conjugate vaccine (PCV7) from 2005, replaced by 13-valent PCV (PCV13) in 2011, uniquely among high-income countries giving doses at 2, 4, and 6 months (3 + 0 schedule). Data on impact of a timely 3 + 0 PCV schedule with high coverage are sparse, with none for PCV13. METHODS: We used national surveillance of invasive pneumococcal disease (IPD) from 2002 for baseline and appropriate later comparison periods to calculate incidence rate ratios (IRRs) by serotype and age using a Poisson model. PCV coverage was assessed from the Australian Childhood Immunisation Register. RESULTS: After 9 years of timely 3-dose PCV coverage of >92%, all-age IPD in Australia almost halved (IRR, 0.53; 95% confidence interval [CI], .50-.57), but differed by PCV era. Reductions in IPD due to vaccine serotypes from PCV7 (IRR, 0.20; CI, .17-.22) were about 2-fold greater than for IPD due to extra serotypes in PCV13 (13v-non7v) in a similar period (IRR, 0.58; CI, .51-.66). Post-PCV13 declines in serotype 19A IPD in persons aged <2 years (IRR, 0.23; CI, .13-.35) and ≥2 years (IRR, 0.35; CI, .28-.44) differed from other 13v-non7v IPD (IRR, 0.73; CI, .35-1.48 for those aged <2 years and IRR, 0.96; CI, .81-1.15 for those ≥2 years). Meningitis due to vaccine serotypes nearly disappeared in children eligible for 3 PCV13 doses. IPD due to non-PCV13 serotypes increased by 30% compared with 76% for non-PCV7 serotypes in equivalent period of vaccine use. CONCLUSIONS: Reductions in vaccine-type IPD post-PCV13 were inferior to Australian experience with PCV7 and reports from high-income countries giving a PCV booster dose. Applicability of findings to other settings would depend on age of IPD onset, serotype profile, and timeliness of vaccination. SN - 1537-6591 UR - https://www.unboundmedicine.com/medline/citation/27986682/Long_term_Impact_of_a_"3_+_0"_Schedule_for_7__and_13_Valent_Pneumococcal_Conjugate_Vaccines_on_Invasive_Pneumococcal_Disease_in_Australia_2002_2014_ DB - PRIME DP - Unbound Medicine ER -
Grapherence [↓25]

Related Citations

More